Stock events for Viatris, Inc. (VTRS)
In the past six months, Viatris's stock price has decreased by 27.26%. Key events impacting the stock include FDA sanctions related to the Indore manufacturing facility, which led to a 15% stock drop and a class action lawsuit. First quarter 2025 financial results showed a slight EPS miss and a revenue miss, but the stock surged due to investor optimism. Second quarter 2024 financial results were strong, leading to an increased outlook for new product revenues. Fourth quarter and full-year 2024 results showed operational revenue growth in line with guidance.
Demand Seasonality affecting Viatris, Inc.’s stock price
Viatris's financial reports acknowledge that products disclosed may change in future periods, including as a result of seasonality, competition, or new product launches. The company's total revenues in the first quarter of 2025 were impacted by the "Indore Impact" and "normal product seasonality", indicating a recognized seasonality in the demand for some of Viatris's products.
Overview of Viatris, Inc.’s business
Viatris Inc. is a global healthcare company formed in November 2020 through the merger of Mylan N.V. and Upjohn, a division of Pfizer. It operates in over 165 countries with a mission to provide sustainable access to high-quality medicines. Viatris has a diverse portfolio of over 1,400 approved molecules, including generics, biosimilars, and branded medicines, addressing various therapeutic areas. Core business segments include Generics and Biosimilars, and Branded Medicines.
VTRS’s Geographic footprint
Viatris has a global presence, delivering medicines to patients in over 165 countries and territories. It operates approximately 40 manufacturing sites worldwide and is headquartered in the U.S., with global centers in Pittsburgh, Shanghai, and Hyderabad. The company's operations are segmented into Developed Markets, Greater China, JANZ, and Emerging Markets.
VTRS Corporate Image Assessment
Viatris has received positive recognition, including being named to Forbes' World's Best Employers 2024 and TIME's World's Best Companies 2023 list, highlighting its focus on employees, sustainability, and growth. However, the FDA sanctions and import alert regarding the Indore manufacturing facility have negatively impacted the company's reputation, leading to a revenue hit and a class action lawsuit.
Ownership
Viatris is primarily owned by institutional shareholders, with significant holdings by Vanguard Group Inc., Blackrock Inc., and Price T Rowe Associates Inc. Institutional ownership ranges from approximately 19.36% to 81.63%, while insiders hold around 0.24% to 18.14%. The largest individual shareholder is Laboratories Abbott, owning 11.57% of the company.
Ask Our Expert AI Analyst
Price Chart
$8.93